Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses

類似資料

• Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
  著者:: Takeshi Yamashita, 等
  出版事項: (2020-06-01)
• Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two‐year postmarketing surveillance study (ETNA‐AF‐Japan)
  著者:: Yamashita, Takeshi, 等
  出版事項: (2021)
• Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
  著者:: Takeshi Yamashita, 等
  出版事項: (2019-02-01)
• Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
  著者:: Yamashita, Takeshi, 等
  出版事項: (2018)
• Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
  著者:: Nagashima, Koichi, 等
  出版事項: (2020)